共查询到20条相似文献,搜索用时 46 毫秒
1.
2.
Percutaneous Ultrasound‐guided Cholecystocentesis and Bile Analysis for the Detection of Platynosomum spp.‐Induced Cholangitis in Cats 下载免费PDF全文
L. Köster L. Shell O. Illanes C. Lathroum K. Neuville J. Ketzis 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2016,30(3):787-793
3.
4.
Treatment of Ionized Hypercalcemia in 12 Cats (2006–2008) Using PO‐Administered Alendronate 下载免费PDF全文
B.T. Hardy J.F. de Brito Galvao T.A. Green S.R. Braudaway S.P. DiBartola L. Lord D.J. Chew 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2015,29(1):200-206
Background
Long‐term treatment of cats with ionized hypercalcemia using alendronate has not been evaluated.Hypothesis/Objectives
Alendronate is well tolerated in treatment of ionized hypercalcemia in cats.Animals
A total of 12 cats with ionized hypercalcemia.Methods
Prospective study of 12 cats with ionized hypercalcemia of idiopathic origin was identified by telephone and email communication with a convenience sample of consulting veterinarians. Cats were treated with alendronate at a dose of 5–20 mg per feline PO q7d. Serum ionized calcium concentration (iCa) was measured before beginning treatment with alendronate, and after 1, 3, and 6 months of treatment. Alendronate dosage was adjusted according to iCa. Evaluation included physical examination, CBC, biochemistry profile, and diagnostic imaging. The owners and referring veterinarians were questioned about any observed adverse effects. The Wilcoxon matched‐pairs signed rank test was used to compare baseline iCa to iCa at different time periods.Results
Alendronate treatment resulted in a decrease in iCa in all 12 cats. The median percentage change in iCa was −13.2%, −15.9%, and −18.1% (range, −29.6 to +7.6; −30.5 to −1.9; −45.8 to +1.5%) at the 1, 3, and 6 month time points, respectively. Baseline iCa was significantly different from 1 month (P = .0042), 3 months (P = .0005), and 6 months (P = .0015). No adverse effects were reported for any of the cats.Conclusions and Clinical Importance
Alendronate was well tolerated and decreased iCa in most cats for the 6‐month period of observation. 相似文献5.
S.J.M. Niessen S. Powney J. Guitian A.P.M. Niessen P.D. Pion J.A.M. Shaw D.B. Church 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2010,24(5):1098-1105
Background: Success in management of diabetes mellitus (DM) is defined as improvement of blood glucose concentrations and clinical signs. However, the psychological and social impact of DM and its daily treatment regimen on quality of life (QoL) of both animal and owner is uncertain. Hypothesis/Objectives: To design, validate, and apply a diabetic pet and owner‐centered, individualized measure of impact of DM (DIAQoL‐pet). Animals/Subjects: Two hundred and twenty‐one owners of insulin‐treated diabetic cats were recruited to complete the DIAQoL‐pet. Methods: Discussions and pilot surveys with clinicians and owners of diabetic cats led to the design of 29 specific DM‐associated QoL questions. Owners of diabetic cats completed the finalized survey. Each item was scored according to impact frequency and perceived importance. An item‐weighted impact score (IWIS) for each item was calculated, as was an average‐weighted impact score (AWIS) by averaging all IWISs. Principal component analysis and Cronbach's α calculation assessed the measure's reliability. Two overview questions measured overall QoL and diabetes‐dependent QoL. Results: The DIAQoL‐pet showed high reliability (Cronbach α 0.83). The AWIS was ?1.76 ± 2.4 (mean ± SD). Areas reported as most negatively impacting QoL included: “boarding difficulties” (IWIS ± SD: ?4.67 ± 5.3), “owner wanting more control” (?4.34 ± 4.7), “difficulties leaving cat with friends or family” (?4.21 ± 4.7), “worry” (?4.10 ± 3.9), “worry hypo” (?3.67 ± 3.5), “social life” (?3.48 ± 3.9), “costs” (?3.04 ± 3.8), and “work life” (?3.03 ± 3.7). Forty‐one percent of owners believed their cat's life would be “a little better” without DM. Conclusions and Clinical Importance: The DIAQoL‐pet proved robust and identified specific areas most negatively impacting on diabetic cats and their owners' QoL. This tool warrants further investigation for use in clinical or research settings. 相似文献
6.
Abdominal Ultrasound Examination Findings in 534 Hyperthyroid Cats Referred for Radioiodine Treatment Between 2007–2010 下载免费PDF全文
L.K. Nussbaum T.D. Scavelli D.M. Scavelli J. Pintar A.K. Henderson J.A. DeMarco S. Worwag R.P. Bastian H.S. Kittner 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2015,29(4):1069-1073
Background
The prevalence of concurrent disease in hyperthyroid cats is unknown.Objectives
To identify the prevalence of concurrent intra‐abdominal disease using abdominal ultrasound examination (AUS) in hyperthyroid cats referred for radioactive iodine treatment (RIT) and to determine whether the requirement for pretreatment AUS is justified.Animals
Five hundred and thirty‐four client‐owned cats diagnosed with hyperthyroidism and referred for RIT.Methods
Retrospective study. Age, breed, sex, body weight, clinical signs, total serum T4 concentration, blood urea nitrogen (BUN) concentration, serum creatinine concentration, urine specific gravity (USG), AUS results, and biopsy or cytology results, or both (if obtained) were collected from the medical records.Results
The prevalence of concurrent disease identified using AUS in hyperthyroid cats referred for RIT was 36.1%; 22.8% of the cats in the study had renal disease and 2.4% had confirmed neoplasia. Significant differences in median USG (P value 0.032) and median BUN (P value 0.028) were found between cats that had abnormal kidneys on AUS compared to those with normal‐appearing kidneys. Only 2.2% of the cats were not treated with RIT as a result of changes identified on AUS and subsequently obtained cytology or biopsy results.Conclusions and Clinical Importance
The results indicate that pretreatment AUS in hyperthyroid cats referred for RIT is unnecessary in most patients. 相似文献7.
Efficacy of Low‐dose (2 millicurie) versus Standard‐dose (4 millicurie) Radioiodine Treatment for Cats with Mild‐to‐Moderate Hyperthyroidism 下载免费PDF全文
J.M. Lucy M.E. Peterson J.F. Randolph P.V. Scrivani M. Rishniw D.L. Davignon M.S. Thompson J.M. Scarlett 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2017,31(2):326-334
8.
9.
10.
The Effect of Orally Administered Ranitidine and Once‐Daily or Twice‐Daily Orally Administered Omeprazole on Intragastric pH in Cats 下载免费PDF全文
S. Šutalo M. Ruetten S. Hartnack C.E. Reusch P. H. Kook 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2015,29(3):840-846
Background
Gastric acid suppressants frequently are used in cats with acid‐related gastric disorders. However, it is not known if these drugs effectively increase intragastric pH in cats.Objectives
To examine the effects of PO administered ranitidine and omeprazole on intragastric pH in cats and to compare the efficacy of once‐daily versus twice‐daily dosage regimens for omeprazole.Animals
Eight domestic shorthair cats.Methods
Using a randomized 4‐way cross‐over design, cats were given enteric‐coated omeprazole granules (1.1–1.3 mg/kg q24h and q12h), ranitidine (1.5–2.3 mg/kg q12h), and placebo. Intragastric pH was monitored continuously for 96 hours using the Bravo™ system1, starting on day 4 of treatment, followed by a median washout period of 12 days. Mean percentage of time pH was ≥3 and ≥4 was compared among groups using repeated measures ANOVA.Results
Mean ± SD percentage of time intragastric pH was ≥3 and ≥4 was 67.0 ± 24.0% and 54.6 ± 26.4% for twice‐daily omeprazole, 24.4 ± 22.8% and 16.8 ± 19.3% for once‐daily omeprazole, 16.5 ± 9.0% and 9.6 ± 5.9% for ranitidine, and 9.4 ± 8.0% and 7.0 ± 6.6% for placebo administration. Twice‐daily omeprazole treatment significantly increased intragastric pH, whereas pH after once‐daily omeprazole and ranitidine treatments did not differ from that of placebo‐treated cats.Conclusion and Clinical Importance
Only twice‐daily PO administered omeprazole significantly suppressed gastric acidity in healthy cats, whereas once‐daily omeprazole and standard dosages of ranitidine were not effective acid suppressants in cats. 相似文献11.
D.W. Hague H.D. Humphries M.A. Mitchell G.D. Shelton 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2015,29(5):1307-1312
Background
Acquired myasthenia gravis (MG) in cats most commonly causes generalized weakness without megaesophagus and is more often associated with a cranial mediastinal mass, compared to dogs.Hypothesis/Objectives
To extend the clinical findings described in the report of 2000 on MG in cats (J Am Vet Med Assoc 215:55–57).Animals
Two hundred and thirty‐five cats with MG.Methods
Retrospective case study to evaluate the long‐term outcome and incidence of spontaneous remission in myasthenic cats. Information including signalment, clinical presentation, presence of and type of cranial mediastinal mass, treatment including surgical versus medical, survival time, and outcome including spontaneous remissions was collected and analyzed in cats diagnosed at the Comparative Neuromuscular Laboratory, University of California San Diego by detection of acetylcholine receptor antibody titers >0.3 nmol/L by immunoprecipitation radioimmunosassay.Results
Acquired MG in cats is associated with a euthanasia rate of 58%. Abyssinian and Somali cats had an increased incidence of MG compared to mixed breed cats or cats of other breeds. A cranial mediastinal mass, most commonly thymoma, was observed in 52% of the cats, which is higher than in the previous report. Spontaneous remission is not a characteristic of MG in cats.Conclusions and clinical importance
Myasthenia gravis in cats is a chronic disease associated with a high incidence of a cranial mediastinal mass. Spontaneous remission is not common and clinicians should warn owners of the necessity for long‐term treatment. The clinical outcome with a cranial mediastinal mass did not differ between surgical or medical treatment. 相似文献12.
A. Pakozdy P. Halasz A. Klang J. Bauer M. Leschnik A. Tichy J.G. Thalhammer B. Lang A. Vincent 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2013,27(1):212-214
Background
Treatment‐resistant complex partial seizures (CPS) with orofacial involvement recently were reported in cats in association with hippocampal pathology. The features had some similarity to those described in humans with limbic encephalitis and voltage‐gated potassium channel (VGKC) complex antibody.Hypothesis/Objectives
The purpose of this pilot study was to evaluate cats with CPS and orofacial involvement for the presence of VGKC‐complex antibody.Animals
Client‐owned cats with acute orofacial CPS and control cats were investigated.Methods
Prospective study. Serum was collected from 14 cats in the acute stage of the disease and compared with 19 controls. VGKC‐complex antibodies were determined by routine immunoprecipitation and by binding to leucine‐rich glioma inactivated 1 (LGI1) and contactin‐associated protein‐like 2 (CASPR2), the 2 main targets of VGKC‐complex antibodies in humans.Results
Five of the 14 affected cats, but none of the 19 controls, had VGKC‐complex antibody concentrations above the cut‐off concentration (>100 pmol/L) based on control samples and similar to those found in humans. Antibodies in 4 cats were directed against LGI1, and none were directed against CASPR2. Follow‐up sera were available for 5 cats in remission and all antibody concentrations were within the reference range.Conclusion and Clinical Importance
Our study suggests that an autoimmune limbic encephalitis exists in cats and that VGKC‐complex/LGI1 antibodies may play a role in this disorder, as they are thought to in humans. 相似文献13.
14.
T.Y. Hui D.S. Bruyette G.E. Moore J.C. Scott‐Moncrieff 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2015,29(4):1063-1068
Background
Exclusive feeding of an iodine‐restricted diet has been proposed as a method for controlling clinical manifestations of hyperthyroidism in hyperthyroid cats.Objectives
To determine the effect of feeding an iodine‐restricted diet on TT4 concentrations and clinical signs in cats with spontaneous hyperthyroidism.Animals
Forty‐nine client‐owned cats with spontaneous hyperthyroidism.Methods
Retrospective case series. Hyperthyroid cats were exclusively fed a commercially available iodine‐restricted diet. Clinical response was assessed by change in weight and heart rate and serum TT4, blood urea nitrogen (BUN), and creatinine concentrations at various times during dietary management (21–60 days, 60–180 days).Results
Serum TT4 normalized in 20/48 cats (42%) and 39/47 cats (83%) at 21–60 days and 61–180 days, respectively. Cats in which the TT4 concentrations were still above reference range at 21–60 days had a significantly higher starting TT4 than those that normalized their TT4 levels during the same time period (P = .038). Body weight did not significantly increase (P = .34) nor heart rate decrease (P = .64) during the study. There was a significant decrease in serum creatinine (P = .028). Cats in the low reference range for serum TT4 concentrations did not have a significant increase in body weight (P = .41) nor creatinine (P = .54) when compared to those with high reference range.Conclusions and Clinical Importance
Restricted‐iodine diets were effective at maintaining serum TT4 concentrations within reference ranges for a majority of cats with spontaneous hyperthyroidism over 1 year, although not all clinical signs of hyperthyroidism improved. 相似文献15.
16.
17.
Investigation of an N‐Terminal Prohormone of Brain Natriuretic Peptide Point‐of‐Care ELISA in Clinically Normal Cats and Cats With Cardiac Disease 下载免费PDF全文
A.N. Harris S.S. Beatty A.H. Estrada B. Winter M. Bohannon I. Sosa J. Hanscom C.A. Mainville A.E. Gallagher 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2017,31(4):994-999
18.
19.
A Feline‐Specific Anti‐Nerve Growth Factor Antibody Improves Mobility in Cats with Degenerative Joint Disease–Associated Pain: A Pilot Proof of Concept Study 下载免费PDF全文
M.E. Gruen A.E. Thomson E.H. Griffith H. Paradise D.P. Gearing B.D.X. Lascelles 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2016,30(4):1138-1148
20.
Relationship between Plasma Fibroblast Growth Factor‐23 Concentration and Survival Time in Cats with Chronic Kidney Disease 下载免费PDF全文
R.F. Geddes J. Elliott H.M. Syme 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2015,29(6):1494-1501